XBRANE Stock Overview
A biotechnology company, engages in the development, manufacture, and sale of biosimilars.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Xbrane Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.29 |
| 52 Week High | kr89.10 |
| 52 Week Low | kr0.18 |
| Beta | 1.08 |
| 1 Month Change | 36.77% |
| 3 Month Change | -47.86% |
| 1 Year Change | -99.63% |
| 3 Year Change | -99.78% |
| 5 Year Change | -99.23% |
| Change since IPO | -99.18% |
Recent News & Updates
Recent updates
Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?
Jun 04
We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully
Nov 05Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)
Mar 24Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings
Mar 02Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price
Feb 10We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth
Jan 12What Kind Of Investors Own Most Of Xbrane Biopharma AB (publ) (STO:XBRANE)?
Dec 16Insider Buying: The Xbrane Biopharma AB (publ) (STO:XBRANE) Head of Manufacturing & Supply Chain Just Bought 50% More Shares
Nov 20Shareholder Returns
| XBRANE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 37.7% | 0.1% | -0.6% |
| 1Y | -99.6% | 8.7% | 17.3% |
Return vs Industry: XBRANE underperformed the Swedish Biotechs industry which returned 6.4% over the past year.
Return vs Market: XBRANE underperformed the Swedish Market which returned 17.4% over the past year.
Price Volatility
| XBRANE volatility | |
|---|---|
| XBRANE Average Weekly Movement | 40.0% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: XBRANE's share price has been volatile over the past 3 months.
Volatility Over Time: XBRANE's weekly volatility has increased from 30% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 93 | Martin Amark | www.xbrane.com |
Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. The company offers Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a certolizumab pegol biosimilar candidate, indicated for the treatment of rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis, Crohn’s disease, and axial spondylitis; Xdivane, a nivolumab biosimilar candidate, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar candidate, indicated for multiple melanoma.
Xbrane Biopharma AB (publ) Fundamentals Summary
| XBRANE fundamental statistics | |
|---|---|
| Market cap | kr446.61m |
| Earnings (TTM) | -kr361.27m |
| Revenue (TTM) | kr190.97m |
2.3x
P/S Ratio-1.2x
P/E RatioIs XBRANE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBRANE income statement (TTM) | |
|---|---|
| Revenue | kr190.97m |
| Cost of Revenue | kr161.51m |
| Gross Profit | kr29.46m |
| Other Expenses | kr390.73m |
| Earnings | -kr361.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 17, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 15.43% |
| Net Profit Margin | -189.18% |
| Debt/Equity Ratio | 45.3% |
How did XBRANE perform over the long term?
See historical performance and comparison